News | August 10, 2024
Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
The latest upgraded Tele Clinic is Artificial Intelligence (AI) - driven to provide healthcare facilities in far flung areas of the region, where such facilities are either not available or inadequately available
The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
With a focus on optimizing patient experience with next-generation oral dosage forms, the US facility complements the cutting-edge research activities of Roquette’s existing pharma innovation centers in France and Singapore
_256_384.jpg){kind=logo}
Veda Corporate Advisors was the exclusive financial advisor to SHPL and its shareholders.
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Subscribe To Our Newsletter & Stay Updated
